Donald Girouard

Donald Girouard

Auto-generated profile, based on publicly available information

Donald Girouard

Department of Infectious Diseases and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SLSangun Lee
Sangun Lee
MGMelanie Ginese
Melanie Ginese
GBGillian Beamer
Gillian Beamer
HDHillary R. Danz
Hillary R. Danz
DGDonald J. Girouard
Donald J. Girouard
STSaul Tzipori
Saul Tzipori
Recent reports highlighting the global significance of cryptosporidiosis among children have renewed efforts to develop control measures. We evaluated the efficacy of bumped kinase inhibitor (BKI) 1369 in the gnotobiotic piglet model of acute diarrhea caused by Cryptosporidium hominis, the species responsible for most human cases. Five day-treatment with BKI 1369 reduced signs of disease early during treatment compared with untreated animals. Piglets treated with BKI 1369 exhibited a significant reduction of oocyst excretion, mucosal colonization by C. hominis, and mucosal lesions, which resulted in considerable symptomatic improvement. BKI 1369 reduced parasite burden and disease severity in the gnotobiotic pig model. Together, these data suggest that the BKI-mediated therapeutic could potentially be an effective treatment against cryptosporidiosis.

1 April 2006 in Journal of Parasitology
Verified
Journal Article
Closed access
DGDonald Girouard
Donald Girouard
JGJennifer Gallant
Jennifer Gallant
DADonna E. Akiyoshi
Donna E. Akiyoshi
JNJohn Nunnari
John Nunnari
STSaul Tzipori
Saul Tzipori
The successful propagation of Cryptosporidium parvum in cell-free culture medium was recently reported. To investigate whether this phenomenon could be broadened to include other C. parvum isolates, as well as Cryptosporidium hominis, we attempted to propagate 3 isolates in cell-free medium under reported culture conditions. Cryptosporidium oocysts from C. parvum strains Moredun (MD) or IOWA or C. hominis strain TU502 were added to media containing coagulated newborn calf serum. The cultures were sampled at various times throughout a 45 (IOWA) or 78 (MD, TU502)-day period and were microscopically examined for various life stages of Cryptosporidium. Cell-free cultures harvested on days 45 and 68 postinoculation were tested for in vitro infectivity on Madrin-Darby bovine kidney cells. In vivo infectivity testing was performed using either infant or 2-wk-old immunosuppressed C57BL mice with cell-free cultures harvested on days 52 and 78. Fecal and gut samples collected from mice were examined by modified acid-fast staining. Data from wet mounts, electron microscopy, and in vitro and in vivo infectivity testing showed that the original oocysts did not complete their life cycle and produce new, viable, infectious oocysts in cell-free culture. Thus, we conclude that this is not a universal phenomenon or readily accomplished.

20 March 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
SLSangun Lee
Sangun Lee
MGMelanie Ginese
Melanie Ginese
DGDon Girouard
Don Girouard
GBGillian Beamer
Gillian Beamer
CHChristopher D Huston
Christopher D Huston
STSaul Tzipori
Saul Tzipori
Background: Cryptosporidiosis, an enteric protozoon, causes substantial morbidity and mortality associated with diarrhea in children 75% of diarrhea reported in these children. Methods: Gnotobiotic piglets were orally challenged with C hominis oocysts, and oral treatment with MMV665917 was commenced 3 days after challenge. Oocyst excretion and diarrhea severity were observed daily, and mucosal colonization and lesions were recorded after necropsy. Results: MMV665917 significantly reduced fecal oocyst excretion, parasite colonization and damage to the intestinal mucosa, and peak diarrheal symptoms, compared with infected untreated controls. A dose of 20 mg/kg twice daily for 7 days was more effective than 10 mg/kg. There were no signs of organ toxicity at either dose, but 20 mg/kg was associated with slightly elevated blood cholesterol and monocytes at euthanasia. Conclusions: These results demonstrate the effectiveness of this drug against C hominis. Piperazine-derivative MMV665917 may potentially be used to treat human cryptosporidiosis; however, further investigations are required.

3 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLSangun Lee
Sangun Lee
MHMelanie Harwood
Melanie Harwood
DGDon Girouard
Don Girouard
MMMarvin J Meyers
Marvin J Meyers
MCMary A Campbell
Mary A Campbell
STSaul Tzipori
Saul Tzipori
Recent reports highlighting the global significance of cryptosporidiosis among children, have renewed efforts to develop control measures. We have optimized the gnotobiotic piglet model of acute diarrhea to evaluate azithromycin (AZR), nitazoxanide (NTZ), or treatment with both against Cryptosporidium hominis, the species responsible for most human cases. Piglets, animals reproducibly clinically susceptible to C. hominis, when inoculated with 106 oocysts, developed acute diarrhea with oocyst excretion in feces within 3 days. Ten day-treatment with recommended doses for children, commencing at onset of diarrhea, showed that treatment with AZR or NTZ relieved symptoms early in the treatment compared with untreated animals. Piglets treated with AZR exhibited no reduction of oocyst excretion whereas treatment with NTZ significantly reduced oocyst shedding early, increasing however after 5 days. While treatment with AZR+NTZ led to considerable symptomatic improvement, it had a modest effect on reducing mucosal injury, and did not completely eliminate oocyst excretion. Doubling the dose of AZR and/or NTZ did not improve the clinical outcome, confirming clinical observations that NTZ is only partially effective in reducing duration of diarrhea in children. This investigation confirms the gnotobiotic piglet as a useful tool for drug evaluation for the treatment of cryptosporidiosis in children.

22 February 2016 in Applied Biosafety
Verified
Journal Article
Open access
DGDonald J. Girouard
Donald J. Girouard
MCMark A. Czarneski
Mark A. Czarneski
The Tufts New England Regional Biosafety Laboratory facility has been using chlorine dioxide gas for >5 years, and >100 decontaminations have been done at the room level and on a Class III cabinet. The rooms have ranged from animal holding rooms containing animal racks (housing rodents and rabbits), biosafety cabinets, and computers to biosafety level 3 laboratories containing a variety of equipment (microscopes, biosafety cabinets, centrifuges, incubators, real-time polymerase chain reaction machines, etc). For a biosafety level 3 facility, the equipment is stainless steel where possible, but there is a variety of materials, including electronics and other sensitive equipment. No corrosion has been experienced on any equipment or surface despite repeated decontaminations. Even the most sensitive equipment has not experienced any ill effects. As a test, when decontaminations were started, a low-cost laptop computer was moved from room to room to a Class III cabinet, decontaminating it every time in each chamber. After 35 repeated exposures, it was still functioning with no issues. It is still in use in one of the animal rooms and gets decontaminated along with the room. The Class III cabinet has not shown any traces of corrosion on the stainless-steel interior, nor has the stainless-steel inhalation exposure system kept inside the cabinet experienced any ill effects.

1 April 2018 in Microbes and Infection
Verified
Journal Article
Open access
ASAbhineet S. Sheoran
Abhineet S. Sheoran
RPRuby Pina-Mimbela
Ruby Pina-Mimbela
AKAlison Keleher
Alison Keleher
DGDonald Girouard
Donald Girouard
STSaul Tzipori
Saul Tzipori
Cryptosporidium hominis and Cryptosporidium parvum are the major Cryptosporidium species that infect humans. Earlier studies in gnotobiotic piglets, model susceptible to both, showed that piglets recovered from infection with C. hominis were fully protected against challenge with same species but incompletely protected against C. parvum challenge. In the present study, piglets were infected with C. parvum first, and after recovery were re-challenged with C. parvum or C. hominis. Again, full protection was only observed when piglets were challenged with the homologous parasite strain. Although the two species are genetically/antigenically almost identical, they do not confer complete protection against each other. Published by Elsevier Masson SAS on behalf of Institut Pasteur.